Arcutis director sells 1,072 shares at $26 each

Q: What insider transaction did ARQT director Terrie Curran report on August 20, 2026?

Terrie Curran reported exercising a stock option for 1,072 shares of Arcutis Biotherapeutics common stock at $7.51 per share and selling 1,072 shares at a weighted average price of $26.0376 per share on August 20, 2026.

Q: At what prices were Terrie Curran’s ARQT shares sold in this Form 4 filing?

The reported sale price for ARQT shares was a weighted average of $26.0376 per share. The shares were sold in multiple transactions at prices ranging from $26.00 to $26.2228 per share.

Q: How many ARQT shares were involved in Terrie Curran’s option exercise and sale?

The transactions involved 1,072 shares of Arcutis Biotherapeutics common stock. Curran exercised options for 1,072 shares and sold 1,072 shares in the same reported sequence.

Arcutis Biotherapeutics, Inc. (ARQT) director Terrie Curran reported an option exercise-and-sale sequence.

Filing Impact

(Neutral)

Filing Sentiment

(Neutral)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Form Type

Rhea-AI Filing Summary

Arcutis Biotherapeutics, Inc. (ARQT) director Terrie Curran reported an option exercise-and-sale sequence. Curran exercised a stock option for 1,072 shares of common stock at an exercise price of $7.51 per share, then sold 1,072 shares of common stock at a weighted average sale price of $26.0376 per share in multiple trades between $26.00 and $26.2228. After the derivative transaction, Curran held 11,148 stock options directly, with the option described as fully vested and expiring on May 31, 2033.

Insider Trade Summary

Exercise and Sale: 1,072 shares ($20K approx. pre-tax spread)

Exercise and Sale 3 txns

Insider Curran Terrie

Role Director

Sold 1,072 shs ($28K)

Approx. gross sale proceeds $28K

Approx. exercise cost $8K

Approx. pre-tax spread $20K

Type	Security	Shares	Price	Value
Exercise	Stock Option (right to buy) ^{F1, F3}	1,072	$0.00	$0.00
Exercise	Common Stock ^F1	1,072	$7.51	$8K
Sale	Common Stock ^{F1, F2}	1,072	$26.0376	$28K

Holdings After Transaction: Stock Option (right to buy) — 11,148 contracts (Direct); Common Stock — 23,526 shares (Direct)

Footnotes (3)

F1. The underlying shares subject to the option vest and become exercisable as to 100% on the first anniversary of May 31, 2023, subject to the non-employee director's continuous service.
F2. The price reported in Column 4 is a weighted average sale price. The shares were sold in multiple transactions at prices ranging from $26.00 to $26.2228, inclusive. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
F3. The option is fully vested.

Key Figures

Options exercised: 1,072 shares Option exercise price: $7.51 per share Shares sold: 1,072 shares +3 more

6 metrics

Options exercised 1,072 shares Stock option for common stock exercised on August 20, 2026

Option exercise price $7.51 per share Exercise price of stock option converted into common stock

Shares sold 1,072 shares Common stock sold on August 20, 2026

Weighted average sale price $26.0376 per share Weighted average price for sales between $26.00 and $26.2228

Remaining stock options 11,148 options Total options held directly following the derivative transaction

Option expiration date May 31, 2033 Expiration date of the exercised stock option

Key Terms

Stock Option (right to buy), weighted average sale price, Exercise or conversion of derivative security, non-employee director

4 terms

Stock Option (right to buy) financial

"security_title: Stock Option (right to buy)"

weighted average sale price financial

"The price reported in Column 4 is a weighted average sale price."

Exercise or conversion of derivative security financial

"transaction_code_description: Exercise or conversion of derivative security"

non-employee director financial

"subject to the non-employee director's continuous service."

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did ARQT director Terrie Curran report on August 20, 2026?

Terrie Curran reported exercising a stock option for 1,072 shares of Arcutis Biotherapeutics common stock at $7.51 per share and selling 1,072 shares at a weighted average price of $26.0376 per share on August 20, 2026.

At what prices were Terrie Curran’s ARQT shares sold in this Form 4 filing?

The reported sale price for ARQT shares was a weighted average of $26.0376 per share. The shares were sold in multiple transactions at prices ranging from $26.00 to $26.2228 per share.

How many ARQT shares were involved in Terrie Curran’s option exercise and sale?

The transactions involved 1,072 shares of Arcutis Biotherapeutics common stock. Curran exercised options for 1,072 shares and sold 1,072 shares in the same reported sequence.

What is the exercise price and expiration date of Terrie Curran’s ARQT stock option?

The stock option exercised by Terrie Curran had an exercise price of $7.51 per share and an expiration date of May 31, 2033. The option is reported as fully vested.

How many ARQT stock options does Terrie Curran hold after the reported transaction?

Following the reported derivative transaction, Terrie Curran held 11,148 stock options for Arcutis Biotherapeutics common stock directly, as disclosed in the filing.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Available on EDGAR 08/24/2026 - 04:21 PM EDT Accepted by SEC EDGAR 08/24/2026 - 04:19 PM EDT

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Curran Terrie

(Last)

(First)

(Middle)

C/O ARCUTIS BIOTHERAPEUTICS, INC.

3027 TOWNSGATE ROAD, SUITE 300

(Street)

WESTLAKE VILLAGE

CALIFORNIA

91361

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Arcutis Biotherapeutics, Inc. [ ARQT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
	Officer (give title below)	Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
08/20/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	08/20/2026		M⁽¹⁾		1,072	A	$7.51	24,598	D
Common Stock	08/20/2026		S⁽¹⁾		1,072	D	$26.0376⁽²⁾	23,526	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Stock Option (right to buy)	$7.51	08/20/2026		M⁽¹⁾			1,072	⁽³⁾	05/31/2033	Common Stock	1,072	$0	11,148	D

Explanation of Responses:

1. The underlying shares subject to the option vest and become exercisable as to 100% on the first anniversary of May 31, 2023, subject to the non-employee director's continuous service.

2. The price reported in Column 4 is a weighted average sale price. The shares were sold in multiple transactions at prices ranging from $26.00 to $26.2228, inclusive. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.

3. The option is fully vested.

Remarks:

	/s/ Latha Vairavan, as Attorney-in-Fact for Terrie Curran	08/24/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR